keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine tumour

keyword
https://www.readbyqxmd.com/read/28099977/a-step-by-step-clinical-approach-for-the-management-of-neuroendocrine-tumours
#1
A Yordanova, H Ahmadzadehfar, M Gonzalez-Carmona, C Strassburg, K Mayer, G Feldmann, I Schmidt-Wolf, R Lingohr, S Fischer, G Kristiansen, M Essler
Neuroendocrine tumours (NET) are rare neoplasms, but the incidence is permanently increasing. Most of the NETs are slow proliferating and clinically silent, and for that reason, they are often diagnosed at a stage with advanced disease. The complexity and diversity of the NET-biology require the treatment of patients in specialised centres to guarantee a qualified, multidisciplinary treatment planning. At our institution, we developed an interdisciplinary model for the assessment and treatment of NET. The aim was to adapt the guidelines to the clinical practice, exchange of current knowledge, and a tailored approach to the individual patient...
January 18, 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28074772/-nuclear-medicine-techniques-for-selective-internal-radiotherapy-of-liver-cancer
#2
Peter Frøhlich Staanum, Anne Kirstine Arveschoug, Stine Maria Jentoft Kramer, Jens Erik Nielsen, Dennis Tønner Nielsen, Peter Ott, Henning Grønbæk, Gerda Elisabeth Villadsen
Selective internal radiation therapy (SIRT) of hepatocellular carcinoma has been introduced at Aarhus University Hospital. 90Y-microspheres are implanted in the tumour by catheterization of the tumour feeding liver artery. Pretreatment angiography and test treatment using 99mTc-labelled particles followed by scintigraphy ensure a feasible and effective treatment. Post-treatment imaging of radiation from 90Y visualize the localization of microspheres. Currently, SIRT is also applied for liver metastases of neuroendocrine tumours...
January 2, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28073908/the-neuroendocrine-sequelae-of-paediatric-craniopharyngioma-a-40-year-meta-data-analysis-of-185-cases-from-three-uk-centres
#3
Timothy Shao Ern Tan, Leena Patel, Jaya Sujatha Gopal-Kothandapani, Sarah Ehtisham, Esieza Clare Ikazoboh, Richard Hayward, Kristian Aquilina, Mars Skae, Nicky Thorp, Barry Pizer, Mohammed Didi, Conor Mallucci, Joanne C Blair, Mark N Gaze, Ian Kamaly-Asl, Helen Spoudeas, Peter E Clayton
Objectives The management of paediatric craniopharyngiomas was traditionally complete resection (CR), with better reported tumour control compared to partial resection (PR) or limited surgery (LS). The subsequent shift towards hypothalamic-sparing, conservative surgery with adjuvant radiotherapy (RT) to any residual tumour, aimed at reducing neuroendocrine morbidity, has not been systematically studied. Hence, we reviewed the sequelae of differing management strategies in paediatric craniopharyngioma across three UK tertiary centres over four decades...
January 10, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28070731/evaluation-of-two-intraoperative-gamma-detectors-for-assessment-of-177-lu-activity-concentration-in-vivo
#4
Viktor Sandblom, Ingun Ståhl, Roger Olofsson Bagge, Eva Forssell-Aronsson
BACKGROUND: Patients with somatostatin receptor-expressing neuroendocrine tumours can be treated with intravenously administered (177)Lu-octreotate. Few patients are cured with the present protocol due to the current dose limitation of normal organs at risk, such as the kidneys. By locally administering (177)Lu-octreotate to the liver for the purpose of treating liver metastases, a substantially reduced absorbed dose to organs at risk could be achieved. The development of such a technique requires the capability of measuring the (177)Lu activity concentration in tissues in vivo...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28069898/is-visual-radiological-evaluation-of-liver-tumour-burden-in-patients-with-neuroendocrine-tumours-reproducible
#5
Magaly Zappa, Olivia Hentic, Marie-Pierre Vullierme, Matthieu Lagadec, Maxime Ronot, Philippe Ruszniewski, Valérie Vilgrain
Background Visual semi-quantitative assessment of liver tumour burden for neuroendocrine tumour liver metastases is often used in patient management and outcome. However, published data on the reproducibility of these evaluations are lacking. Objective The aim of this study was to evaluate the inter and intraobserver agreement of a visual semi-quantitative assessment of liver tumour burden using CT scan. Methods Fifty consecutive patients (24 men and 26 women, mean age 54 years old) were retrospectively reviewed by four readers (two senior radiologists, one junior radiologist and one gastroenterologist) who assessed the liver tumour burden based on visual a semi-quantitative method with four classes (0-10%, 11-25%, 26-50%, and ≥50%)...
January 9, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28062742/emphysematous-cholecystitis-in-a-patient-with-metastatic-pancreatic-neuroendocrine-tumour
#6
M Khan, M Little, G Campbell, H-U Laasch, T Cooksley
No abstract text is available yet for this article.
January 5, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28049633/progressive-epigenetic-dysregulation-in-neuroendocrine-tumour-liver-metastasis
#7
Anna Karpathakis, Harpreet Dibra, Christodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua M Francis, Dahmane Oukrif, Dalvinder Mandair, Marinos Pericleous, Mullan Mohmaduvesh, Stefano Serra, Olagunju Ogunbiyi, Marco Novelli, Tu Vinh Luong, Sylvia L Asa, Matthew H Kulke, Christos Toumpanakis, Tim Meyer, Martyn Caplin, Stephan Beck, Christina Thirlwell
Dear Editor The incidence of small intestinal neuroendocrine tumours (SINETs) is increasing and distant metastases are present at diagnosis in 70% of cases, the liver being the most common site of metastasis. Despite this, our understanding of the mechanisms underlying metastatic progression of SINETs is currently limited and prior studies of the molecular biology of SINET liver metastases (LM) have been performed predominantly in small cohorts utilising candidate based techniques.
January 3, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28040707/stridor-secondary-to-a-subglottic-neuroendocrine-tumour
#8
Daniel W Scholfield, S Virk Jagdeep, Paul Stimpson
Large cell neuroendocrine carcinoma is a rare high-grade neuroendocrine neoplasm of the larynx, that exhibits particularly aggressive behaviour. We present a case of a 42-year-old patient with progressive dyspnoea and biphasic stridor, initially treated as asthma and resulting in delayed definitive management. Flow volume loops demonstrated narrowed inspiratory and expiratory flow volume loops. Subsequent CT neck and thorax indicated a mass arising from the subglottis and the patient proceeded to microlaryngoscopy and trans-oral CO2 laser debulking...
December 30, 2016: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28027897/relevance-of-dihydropyrimidine-dehydrogenase-and-thymidylate-synthase-in-patients-with-pancreatic-neuroendocrine-neoplasms-treated-with-5-fu-based-chemotherapy
#9
S Krug, M Boch, W Nimphius, T M Gress, P Michl, A Rinke
BACKGROUND: Chemotherapy with 5-FU and Streptozotocin (STZ) is recommended as first-line treatment in patients with metastatic pancreatic neuroendocrine neoplasms (PNEN). However, data about biomarkers involved in the 5-FU metabolism to predict response are still limited. OBJECTIVES: Evaluation of clinicopathological features and potential predictive and prognostic markers of patients with PNEN treated with 5-FU based regimens. PATIENTS AND METHODS: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013...
December 22, 2016: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/28026127/well-differentiated-bronchial-neuroendocrine-tumors-clinical-management-and-outcomes-in-105-patients
#10
Marinos Pericleous, Anna Karpathakis, Christos Toumpanakis, Heather Lumgair, Jonathan Reiner, Laura Marelli, Christina Thirlwell, Martyn E Caplin
INTRODUCTION: Bronchial neuroendocrine tumors (NETs) are rare tumors representing approximately 20%-30% of all neuroendocrine tumors and 2%-3% of all adult lung cancers. Here, they present a large case series of well-differentiated bronchial NETs with the aim of investigating the behavior of these tumors and long-term outcomes. METHODS: A retrospective review was performed of 105 patients with bronchial NETs managed in a tertiary referral center in the period between January 1998 and January 2012...
December 27, 2016: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/27999073/prognostic-impact-of-tumour-size-in-completely-resected-thymic-epithelial-tumours
#11
Takayuki Fukui, Koichi Fukumoto, Toshiki Okasaka, Koji Kawaguchi, Shota Nakamura, Shuhei Hakiri, Naoki Ozeki, Akihiro Hirakawa, Hisashi Tateyama, Kohei Yokoi
OBJECTIVES: The T descriptor of thymic epithelial tumours proposed by the International Association for the Study of Lung Cancer and the International Thymic Malignancy Interest Group as well as the Masaoka-Koga system is defined by the anatomical extent of primary tumours, regardless of their size. However, the prognostic significance of tumour size in thymic epithelial tumours has not been fully elucidated. METHODS: We evaluated the prognostic significance of tumour size in 154 consecutive patients with thymic epithelial tumours including 124 thymomas, 21 thymic carcinomas and 9 neuroendocrine tumours, who underwent complete resection between 2001 and 2014...
December 2016: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/27973344/objective-comparison-of-lesion-detectability-in-low-and-medium-energy-collimator-iodine-123-mibg-images-using-a-channelized-hotelling-observer
#12
Rebecca A Gregory, Iain Murray, Jonathan Gear, Matthew D Aldridge, Daniel Levine, Lucy Fowkes, Wendy A Waddington, Sue Chua, Glenn Flux
Iodine-123 mIBG imaging is widely regarded as a gold standard for diagnostic studies of neuroblastoma and adult neuroendocrine cancer although the optimal collimator for tumour imaging remains undetermined. Low-energy (LE) high-resolution (HR) collimators provide superior spatial resolution. However due to septal penetration of high-energy photons these provide poorer contrast than medium-energy (ME) general-purpose (GP) collimators. LEGP collimators improve count sensitivity. The aim of this study was to objectively compare the lesion detection efficiency of each collimator to determine the optimal collimator for diagnostic imaging...
January 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27972467/cost-of-illness-of-metastatic-gastroenteropancreatic-neuroendocrine-tumours-in-sweden-a-register-linkage-population-based-study
#13
E Lesén, D Granfeldt, A Houchard, A Berthon, J Dinet, Å Björstad, I Björholt, A Elf, V Johanson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27959889/childhood-neuroendocrine-tumours-a-descriptive-study-revealing-clues-for-genetic-predisposition
#14
I J Diets, I D Nagtegaal, J Loeffen, I de Blaauw, E Waanders, N Hoogerbrugge, M C J Jongmans
BACKGROUND: Neuroendocrine tumours (NETs) are rare in children and limited data are available. We aimed to specify tumour and patient characteristics and to investigate the role of genetic predisposition in the aetiology of paediatric NETs. METHODS: Using the Dutch Pathology Registry PALGA, we collected patient- and tumour data of paediatric NETs in the Netherlands between 1991 and 2013 (N=483). RESULTS: The incidence of paediatric NETs in the Netherlands is 5...
January 17, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/27956320/primary-tumour-resection-may-improve-survival-in-functional-well-differentiated-neuroendocrine-tumours-metastatic-to-the-liver
#15
D Citterio, S Pusceddu, A Facciorusso, J Coppa, M Milione, R Buzzoni, M Bongini, F deBraud, V Mazzaferro
BACKGROUND: Functional well-differentiated neuroendocrine tumours (NET) with liver metastases represent a therapeutic challenge with few alternative options in guidelines. In these patients, the role of surgical resection of the primary tumour is controversial. PATIENTS AND METHODS: From a regional registry collecting somatostatin analogue (SSA)-treated tumours from 1979 to 2005, a series of 139 patients presenting with symptomatic, liver-metastatic, well-differentiated NET (G1-G2, mitoses: ≤20, Ki-67: ≤20%) was prospectively collected and retrospectively analysed...
November 24, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27932068/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent-small-cell-lung-cancer-a-first-in-human-first-in-class-open-label-phase-1-study
#16
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, Neal Ready, Daniel Morgensztern, Bonnie S Glisson, Lauren A Byers, Melissa L Johnson, Howard A Burris, Francisco Robert, Tae H Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K Strickland, Ramaswamy Govindan, Scott J Dylla, Stanford L Peng, David R Spigel
BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen. METHODS: We conducted a phase 1 open-label study at ten cancer centres in the USA...
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27925203/the-genetic-landscape-of-breast-carcinomas-with-neuroendocrine-differentiation
#17
Caterina Marchiò, Felipe C Geyer, Charlotte Ky Ng, Salvatore Piscuoglio, Maria R De Filippo, Marco Cupo, Anne M Schultheis, Raymond S Lim, Kathleen A Burke, Elena Guerini-Rocco, Mauro Papotti, Larry Norton, Anna Sapino, Britta Weigelt, Jorge S Reis-Filho
Neuroendocrine breast carcinomas (NBCs) account for 2-5% of all invasive breast cancers, and are histologically similar to neuroendocrine tumours from other sites. They typically express oestrogen receptor (ER), and are HER2-negative and of luminal 'intrinsic' subtype. Here, we sought to define the mutational profile of NBCs, and to investigate whether NBCs and common forms of luminal (ER(+) /HER2(-) ) breast carcinoma show distinct repertoires of somatic mutations. Eighteen ER(+) /HER2(-) NBCs, defined as harbouring >50% of tumour cells expressing chromogranin A and/or synaptophysin, and matched normal tissues were microdissected and subjected to massively parallel sequencing targeting all exons of 254 genes most frequently mutated in breast carcinomas and/or related to DNA repair...
December 7, 2016: Journal of Pathology
https://www.readbyqxmd.com/read/27922042/neuroendocrine-tumours-in-2016-defining-rules-for-increasingly-personalized-treatments
#18
Massimo Falconi, Stefano Partelli
No abstract text is available yet for this article.
December 6, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27917670/neuroendocrine-tumour-arising-inside-a-tailgut-cyst
#19
I Mora-Guzmán, A Alonso-Casado, A Rodríguez Sánchez, E Bermejo Marcos
Tailgut cysts are rare benign retrorectal cysts arising from persistent remnants of an embryonic hindgut. Malignant transformation inside this lesion is very uncommon and occurrence of neuroendocrine tumours in this context is extremely rare. We report the case of a 56-year-old woman who underwent surgical excision of a presacral tailgut cyst, which was found incidentally to include a neuroendocrine tumour.
December 5, 2016: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/27904871/in-vivo-measurement-and-characterization-of-a-novel-formulation-of-177-lu-dota-octreotate
#20
Dale L Bailey, Thomas M Hennessy, Kathy P Willowson, E Courtney Henry, David Lh Chan, Alireza Aslani, Paul J Roach
OBJECTIVES: Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" (NCA) (177)Lu. We have radiolabelled DOTA-conjugated peptide DOTA-(Tyr(3))-octreotate with NCA (177)Lu ("NCA-LuTATE") and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) (177)Lu imaging...
2016: Asia Oceania Journal of Nuclear Medicine & Biology
keyword
keyword
13159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"